|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
GlaxoSmithKline |
| Information provided by: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT00549211 |
Purpose
A study conducted on healthy volunteers to determine the safety, tolerability and affect on the human body by experimental drug GSK557296.
| Condition | Intervention | Phase |
|
Premature Ejaculation |
Drug: GSK557296 |
Phase I |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Single Blind, Placebo Control, Crossover Assignment, Pharmacokinetics Study |
| Official Title: | A Two-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of GSK557296 in a Randomized, Single-Blind, Placebo-Controlled, Dose-Rising Design, and to Evaluate the Effect of Food on Single Oral Doses of GSK557296 in Healthy Adult Subjects |
| Estimated Enrollment: | 42 |
| Study Start Date: | October 2007 |
Eligibility
| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Indiana | |||||
| GSK Clinical Trials Call Center | Not yet recruiting | ||||
| Evansville, Indiana, United States, 47714 | |||||
| Contact: Stewart Smith 877-379-3718 | |||||
| GlaxoSmithKline |
| Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
More Information
| Study ID Numbers: | OTB109039 |
| First Received: | October 23, 2007 |
| Last Updated: | October 23, 2007 |
| ClinicalTrials.gov Identifier: | NCT00549211 |
| Health Authority: | United States: Food and Drug Administration |
|
|